The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement

26 Mar 2021 16:01

RNS Number : 6999T
Iconic Labs PLC
26 March 2021
 

26 March 2021

Iconic Labs Plc ("Iconic Labs" or the "Company")

 

Settlement reached with European High Growth Opportunities Securitization Fund ("EHGOF")

 

Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business announces that it has today signed a settlement agreement with EHGOF with respect to claims made by EHGOF in connection with alleged breaches of various finance agreements that the Company had entered into with EHGOF.

 

Pursuant to the terms of the settlement agreement (I) the Company has agreed to (a) be bound by the agreements previously entered into with EHGOF; (b) issue an additional 80 convertible notes (equivalent to £800,000) together with an appropriate number of warrants under the terms of the finance agreements shortly after the signing of the settlement deed; (c) issue a prospectus within 3 months of the date of the settlement agreement and convene a general meeting of shareholders to obtain relevant corporate approvals relating to the issuance of shares under the agreements entered into with EHGOF; (d) buy back any warrants where the Company has insufficient corporate authorities to issue shares; (e) a right of first offer in favour of EHGOF with respect to any future variable rate equity financing that the Company may undertake; and (f) make certain corporate governance changes (such as the changes to the board of directors as have been recently announced by the Company) and (g) to pursue various claims and actions against certain former directors of the Company for loss or damage inflicted on the Company; (II) EHGOF has agreed to provide the Company, within 2 business days of the date of the settlement agreement, with an interim loan of £310,000 in order to fund the Company's issuance of a prospectus and to pay certain other amounts (and such loan is to be refinanced through the issuance of 31 convertible notes to EHGOF; (III) the exercise price of the previously issued warrants (with an exercise price higher than GBP0.0001) is amended to GBP0.0001; and (IV) all warrants issued prior to the date of the settlement agreement are amended such that the end of the warrant exercise period with respect to all such warrants is extended to the date which falls five years from the date of the settlement agreement. EHGOF retains certain rights against the Company if it breaches the agreement, including the right to commence proceedings to enforce all claims against the Company. Provided certain conditions are met by Iconic, EHGOF has agreed to an order being filed which stays the proceedings.

 

"Settling these claims with EHGOF was an immediate priority for the board and me this week. We are pleased with the terms we have negotiated and look forward to continuing to work productively with EHGOF," said Brad Taylor. 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

**ENDS**

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Iconic Labs ir@iconiclabs.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRFLFEEVTIRFIL
Date   Source Headline
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023
24th Oct 20235:31 pmRNSChange of Auditor
17th Oct 20237:51 amRNSConversion of Securities
13th Oct 202311:32 amRNSAnnouncement of the Completion of CVA
13th Oct 202311:30 amRNSConversion of Securities
29th Sep 20238:01 amRNSTotal Voting Rights
22nd Sep 20239:40 amRNSConversion of Securities
18th Sep 20236:27 pmRNSConversion of Notes – Replacement
18th Sep 20237:37 amRNSConversion of Securities
12th Sep 20238:45 amRNSStatement re CVA
4th Sep 202312:02 pmRNSConversion of Securities
31st Aug 20237:21 amRNSTotal Voting Rights
25th Aug 20234:49 pmRNSResult of AGM
18th Aug 20237:51 amRNSConversion of Securities
14th Aug 20237:59 amRNSIssue of Debt
8th Aug 20232:58 pmRNSPublication of a Prospectus
4th Aug 20234:19 pmRNSNotice of AGM
30th Jun 20239:12 amRNSTotal Voting Rights
2nd Jun 20231:20 pmRNSIssue of Equity
28th Apr 202310:35 amRNSTotal Voting Rights
12th Apr 20238:13 amRNSConversion of Securities
31st Mar 20233:11 pmRNSTotal Voting Rights
31st Mar 20231:59 pmRNSHalf-year Report
29th Mar 20232:05 pmRNSSecond Price Monitoring Extn
29th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Mar 20237:42 amRNSConversion of Securities
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 202311:48 amRNSSubscription of Convertible Notes
21st Mar 202311:05 amRNSSecond Price Monitoring Extn
21st Mar 202311:00 amRNSPrice Monitoring Extension
21st Mar 20239:05 amRNSSecond Price Monitoring Extn
21st Mar 20239:00 amRNSPrice Monitoring Extension
20th Mar 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.